MERIT MEDICAL SYSTEMS INC

(c)On August 24, 2026, Michel Voigt, Chief Human Resources Officer, modified a trading arrangement (the “Voigt Rule 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Pursuant to Exchange Act Rule 10b5-1(c)(1)(iv), the modification is considered a termination of the existing trading arrangement and theadoption of a new trading arrangement. The Voigt Rule 10b5-1 Trading Plan provides for the sale of up to 7,682 shares of Common Stock issued or issuable under the terms of certain performance share awards and restricted stock awards granted to Mr. Voigt by Merit. The Voigt Rule 10b5-1 Trading Plan will terminate on May 12, 2027, unless terminated earlier pursuant to the terms of the Voigt Rule 10b5-1 Trading Plan.

Other than with respect to the Voigt Rule 10b5-1 Trading Plan, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, during the three-month period ended September 30, 2026.